FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) - Analysts at Leerink Partnrs increased their FY2026 earnings per share estimates for shares of Zai Lab in a report released on Monday, June 30th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn $0.33 per share for the year, up from their previous estimate of $0.29. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share.

Several other equities research analysts have also weighed in on ZLAB. JPMorgan Chase & Co. increased their target price on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, March 13th. Wall Street Zen cut shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Scotiabank started coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th. Finally, Leerink Partners set a $75.00 price target on Zai Lab and gave the company an "outperform" rating in a report on Monday, June 30th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Zai Lab presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.28.

Zai Lab Trading Up 2.6%

ZLAB traded up $0.94 on Wednesday, hitting $36.43. 581,960 shares of the company's stock were exchanged, compared to its average volume of 914,335. The stock has a fifty day moving average of $33.80 and a two-hundred day moving average of $31.42. The firm has a market cap of $4.05 billion, a PE ratio of -14.63 and a beta of 0.99. Zai Lab has a twelve month low of $16.01 and a twelve month high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.05. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. The firm had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million.

Insider Buying and Selling

In related news, CEO Ying Du sold 7,072 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $35.23, for a total transaction of $249,146.56. Following the sale, the chief executive officer owned 536,962 shares of the company's stock, valued at $18,917,171.26. The trade was a 1.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William Lis sold 13,814 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.67, for a total value of $492,745.38. Following the completion of the sale, the director owned 35,106 shares of the company's stock, valued at $1,252,231.02. This trade represents a 28.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 160,155 shares of company stock valued at $4,959,535 over the last 90 days. 4.96% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zai Lab

Several hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in Zai Lab during the first quarter valued at about $1,073,000. MPM Bioimpact LLC lifted its holdings in Zai Lab by 4.2% in the 1st quarter. MPM Bioimpact LLC now owns 833,659 shares of the company's stock valued at $30,128,000 after acquiring an additional 33,659 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new position in shares of Zai Lab during the 1st quarter valued at about $12,649,000. Cubist Systematic Strategies LLC boosted its position in shares of Zai Lab by 29.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock valued at $3,384,000 after purchasing an additional 21,026 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Zai Lab by 214.3% in the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock worth $498,000 after purchasing an additional 9,390 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.